TrialInvestigational new drugs2005

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

G Goss et al.PubMed ↗Publisher ↗

No numbers read from the abstract.